Your browser doesn't support javascript.
loading
Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager.
Anbari, Samira; Wang, Hanwen; Zhang, Yu; Wang, Jun; Pilvankar, Minu; Nickaeen, Masoud; Hansel, Steven; Popel, Aleksander S.
Afiliación
  • Anbari S; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Wang H; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Zhang Y; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Wang J; Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Pilvankar M; Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Nickaeen M; Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Hansel S; Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Popel AS; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Pharmacol ; 14: 1163432, 2023.
Article en En | MEDLINE | ID: mdl-37408756
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos